Popular GLP-1 medications such as Ozempic and Wegovy are best known for treating diabetes and obesity, but emerging research is examining whether they may also offer benefits related to cancer. A breast cancer surgeon says the drugs could potentially help reduce the risk of breast cancer returning.
The possible connection appears to involve several effects associated with weight loss. By lowering body mass index, GLP-1 medicines may reduce estrogen levels and inflammation, factors that can influence breast cancer risk and recurrence.
The findings remain an area of developing research, rather than proof that the medications prevent cancer. Their established uses are diabetes and obesity treatment, while researchers continue to assess whether the broader metabolic changes linked to GLP-1 drugs translate into meaningful cancer protection.
